3 Over the Counter and Prescription Drug Maker, Plastic Piping Systems Maker and Passenger Car Leader Stocks With a Strong Future Roadmap: Marksans Pharma, Astral and Maruti Suzuki

OTC drug, plastic pipe and passenger car stocks give investors a way to track businesses that sit close to everyday demand in India. Marksans Pharma, Astral and Maruti Suzuki cover an over the counter and prescription drug maker, a plastic piping systems maker and a passenger car leader.

This list covers three OTC drug, plastic pipe and passenger car stocks with complete current figures: Marksans Pharma, Astral and Maruti Suzuki. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are OTC Drug, Plastic Pipe and Passenger Car Stocks?

OTC drug, plastic pipe and passenger car stocks are listed companies that make over-the-counter and prescription formulations, produce CPVC and PVC pipes, adhesives and bathware, and sell hatchbacks, sedans and utility vehicles through a vast sales and service network. Their earnings depend on export approvals, building activity and car demand.

OTC Drug, Plastic Pipe and Passenger Car Stocks at a Glance

On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Astral and Maruti Suzuki trade above it, which reflects the growth the market already expects. Readers comparing OTC drug, plastic pipe and passenger car stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in OTC drug, plastic pipe and passenger car stocks can use the coming numbers to test whether growth is holding.

Why Do OTC Drug, Plastic Pipe and Passenger Car Stocks Have a Strong Roadmap in India?

OTC drug, plastic pipe and passenger car stocks have a strong roadmap in India because steady demand for generics overseas, growing building activity and a healthy car market keep widening the market for these companies.

• Generics. Regulated markets buy dependable supply.
• Plastic pipes. Homes and cities need piping.
• Cars. A wide network supports steady sales.

Why Marksans Pharma Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks

Among the OTC drug, plastic pipe and passenger car stocks on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.

In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.

Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.

Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

What to watch: Track export growth, new product approvals and plant utilisation.

Why Astral Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks

Among the pharma, building and auto shares on this list, Astral is a leading maker of plastic piping systems and building products, with CPVC and PVC pipes, adhesives, sealants and bathware sold through a wide distribution network.

The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P/E of 66.5, above the industry P/E of 36.4.

Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore.

Roadmap: The company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.

What to watch: Watch PVC resin price trends and growth in the adhesives and paints businesses.

Why Maruti Suzuki Features Among These OTC Drug, Plastic Pipe and Passenger Car Stocks

Among the three companies on this list, Maruti Suzuki is India's largest passenger car maker, selling a wide range of hatchbacks, sedans and utility vehicles through a vast sales and service network, and it also exports cars to many countries.

Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%.

In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P/E of 24.7, above the industry P/E of 23.4.

Roadmap: The company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.

What to watch: Follow monthly sales, utility vehicle mix, export volumes and progress on electric models.

Marksans Pharma vs Astral vs Maruti Suzuki on Key Financials

The table below sets the three OTC drug, plastic pipe and passenger car stocks side by side on revenue, profit and margin, using reported figures.

Marksans Pharma posts the highest return on equity in this group at 13.8%. Maruti Suzuki combines the largest FY26 revenue at Rs 187,673 crore with the fastest revenue growth, a 20.1% compound annual rate. A useful habit with OTC drug, plastic pipe and passenger car stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several generic medicine, CPVC pipe and hatchback stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in OTC Drug, Plastic Pipe and Passenger Car Stocks

Every theme carries risks that deserve a check before any decision. For these OTC drug, plastic pipe and passenger car stocks, the main points are: Long-term pharma, building and auto shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Input costs. Metal and material prices can move margins.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter OTC drug, plastic pipe and passenger car stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on OTC Drug, Plastic Pipe and Passenger Car Stocks

OTC drug, plastic pipe and passenger car stocks work best when investors track growth, valuation and return on equity side by side. Marksans Pharma, Astral and Maruti Suzuki each have a clear plan to grow. Based on the 4 November 2026 close, Marksans Pharma trades at Rs 301.65, Astral at Rs 1,423.7 and Maruti Suzuki at Rs 11,995. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these OTC drug, plastic pipe and passenger car stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track OTC drug, plastic pipe and passenger car stocks, set price alerts and get research-backed stock ideas.

What are OTC drug, plastic pipe and passenger car stocks?

Ans. OTC drug, plastic pipe and passenger car stocks are listed companies that make over-the-counter and prescription formulations, produce CPVC and PVC pipes, adhesives and bathware, and sell hatchbacks, sedans and utility vehicles through a vast sales and service network. Their earnings depend on export approvals, building activity and car demand. This list looks at three of them, Marksans Pharma, Astral and Maruti Suzuki, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.

Which OTC drug, plastic pipe and passenger car stocks are covered in this list?

Ans. This list covers Marksans Pharma, Astral and Maruti Suzuki. Based on the 4 November 2026 close, Marksans Pharma traded at Rs 301.65, Astral at Rs 1,423.7 and Maruti Suzuki at Rs 11,995. Their return on equity ranges from 13.2% to 13.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.6% to 20.1%.

Why do OTC drug, plastic pipe and passenger car stocks have a strong future roadmap in India?

Ans. OTC drug, plastic pipe and passenger car stocks have a strong roadmap in India because steady demand for generics overseas, growing building activity and a healthy car market keep widening the market for these companies. The main drivers are as follows. Generics. Regulated markets buy dependable supply. Plastic pipes. Homes and cities need piping. Cars. A wide network supports steady sales. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Marksans Pharma performed financially?

Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.

How has Astral performed financially?

Ans. Revenue rose from Rs 4,429 crore in FY22 to Rs 6,616 crore in FY26, a compound annual growth rate of 10.6%. Net profit grew from Rs 460 crore in FY23 to Rs 535 crore in FY26, which works out to a compound annual growth rate of 5.2%. In the June 2026 quarter, revenue grew 16.1% year on year to Rs 1,591 crore, while net profit rose 51.8% to Rs 120 crore. The company has a return on equity of 13.2%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 38,267 crore. The stock trades at a P/E of 66.5, above the industry P/E of 36.4. Looking ahead, the company has widened from plumbing pipes to adhesives, paints and bathware, which lifts revenue per customer. Capacity additions and an extensive dealer network position it well for housing and infrastructure demand.

How has Maruti Suzuki performed financially?

Ans. Revenue rose from Rs 90,074 crore in FY22 to Rs 187,673 crore in FY26, a compound annual growth rate of 20.1%. Net profit grew from Rs 3,880 crore in FY22 to Rs 14,680 crore in FY26, which works out to a compound annual growth rate of 39.5%. In the June 2026 quarter, revenue grew 34.2% year on year to Rs 54,344 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 353,984 crore. The stock trades at a P/E of 24.7, above the industry P/E of 23.4. Looking ahead, the company is widening its utility vehicle range, adding hybrid and electric models and growing its exports from new capacity. A trusted brand and wide service reach support demand among first-time and repeat buyers.

What risks should investors check before buying OTC drug, plastic pipe and passenger car stocks?

Ans. Investors should check a few risks before buying OTC drug, plastic pipe and passenger car stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Input costs. Metal and material prices can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of OTC drug, plastic pipe and passenger car stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.